Our strategy is to focus mainly, but not exclusively, on two core disorders associated with abnormal cognitive and social development: autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). The aim is to enable more rapid diagnosis and improve treatment of individuals with these disorders.
Neurodevelopmental disorders such as ASD and ADHD are high-cost disorders with a substantial unmet need. Diagnostic tests and treatments throughout the life course, from infancy through to adulthood, are desperately needed.
We believe that it is only by responding comprehensively to the changing needs of people with neurodevelopmental disorders throughout life that the clinical community will be able to offer patients truly personalised care.
Early intervention: to advance our understanding of the origin, biological mechanism and lifespan evolution of challenging neurodevelopmental disorders; to understand how these are associated with mental health problems and antisocial behaviour in order to promote early intervention.
Diagnostic and predictive tools: to develop and evaluate novel imaging, genetic, and biomarkers to help us more accurately diagnose, and predict disease onset and treatment response in ADHD and ASD.
Novel interventions: to discover and test novel psycho-pharmacologic and psychological interventions for ADHD, ASD, and psychopathy.